Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Surg Case Rep ; 2024(7): rjae455, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38993815

ABSTRACT

Rosai-Dorfman disease presenting solely with intrathoracic lesions is exceptionally rare. Herein, we report the case of a 53-year-old man presenting with a posterior mediastinal tumour. Computed tomography revealed a 7-cm soft tissue shadow in the posterior mediastinum. Positron emission tomography-computed tomography demonstrated a high maximum standardized uptake value of 10.35 in the tumour, with no evidence of lymph node or other organ involvement. Serum marker levels were within the normal range. Thoracoscopic surgery was performed to obtain a biopsy for a definitive diagnosis and treatment planning. Postoperative histological findings revealed a diffuse infiltration of eosinophilic histiocytes, lymphocytes, and plasma cells. Immunohistochemical analysis indicated positivity for S-100 protein, oct-2, and cyclin D1 in these histiocytes. Consequently, the patient was diagnosed with Rosai-Dorfman disease and is currently asymptomatic, undergoing regular monitoring without treatment as an outpatient. The absence of characteristic findings, such as bilateral cervical lymphadenopathy, posed challenges in preoperative diagnosis.

2.
J Surg Case Rep ; 2022(10): rjac466, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36245559

ABSTRACT

A 75-year-old female patient was referred to our hospital due to an abnormal shadow detected by chest X-ray. Computed tomography scans revealed a well-circumscribed nodule measuring 28 mm between B4 and B5 in the right middle lobe. Because the tumor was in the center of right middle lobe, a middle lobe resection was performed. The tumor was located within the lung and there were no obvious pleural surface changes. Postoperative histological findings showed 34-mm firm and round tumor, and well circumscribed without involving the visceral pleura. The pathologic examination revealed proliferating spindle-shaped cells with a random fascicular arrangement with continuity to the pulmonary interstitium. Not much cellular atypia was observed. Immunohistochemical staining indicated that the tumor was positive for STAT6, CD34. The final diagnosis was an intrapulmonary benign solitary fibrous tumor (SFT). Even benign intrapulmonary SFTs that have been completely resected may later become malignant and recur, and careful follow-up is necessary.

3.
Breast Cancer ; 27(5): 929-937, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32270417

ABSTRACT

BACKGROUND: Upper-limb lymphedema is a well-known complication of breast cancer and its treatment. This retrospective cohort study aims to determine what risk factors affect breast cancer-related lymphedema in patients with breast cancer. METHODS: This retrospective study comprised patients diagnosed with breast cancer and who underwent surgery at Wakayama Medical University Hospital between January 1, 2012 and December 31, 2018. Assessed factors using univariate and multivariate analyses were patient-related factors (age, gender, and BMI), breast cancer-related factors (tumor size, nodal status, histology, tumor location, and intrinsic subtype), and treatment-related factors (type of surgery, application, timing and regimen of chemotherapy, and application of radiotherapy). RESULTS: This study included 1041 patients. BMI did not affect the onset of breast cancer-related lymphedema. There were only six sentinel lymph node biopsy cases in the breast cancer-related lymphedema group (6.6%). In cases of axillary lymph node dissection, adjuvant chemotherapy was marginally associated with increased risk of breast cancer-related lymphedema compared to no chemotherapy (HR 2.566; 95% CI 0.955-6.892; p = 0.0616). Among anti-cancer agents, docetaxel (HR 3.790; 95% CI 1.413-10.167; p = 0.0081) and anti-HER2 therapy (HR 2.507; 95% CI 1.083-5.803; p = 0.0318) were associated with increased risk of lymphedema according to multivariate analysis. Neo-adjuvant chemotherapy did not affect the onset of breast cancer-related lymphedema. Radiotherapy (HR 2.525; 95% CI 1.364-4.676; p = 0.0032) was an important risk factor for breast cancer-related lymphedema. CONCLUSIONS: Axillary lymph node dissection, radiotherapy and adjuvant chemotherapy, especially docetaxel, were risk factors for breast cancer-related lymphedema, but BMI and neo-adjuvant chemotherapy were not.


Subject(s)
Breast Cancer Lymphedema/epidemiology , Breast Neoplasms, Male/therapy , Breast Neoplasms/therapy , Docetaxel/adverse effects , Mastectomy/adverse effects , Adult , Age Factors , Aged , Aged, 80 and over , Axilla , Body Mass Index , Breast Cancer Lymphedema/etiology , Chemoradiotherapy, Adjuvant/adverse effects , Chemoradiotherapy, Adjuvant/methods , Chemotherapy, Adjuvant/adverse effects , Chemotherapy, Adjuvant/methods , Female , Follow-Up Studies , Humans , Lymph Node Excision/adverse effects , Lymph Nodes/pathology , Lymph Nodes/surgery , Male , Mastectomy/methods , Middle Aged , Neoadjuvant Therapy/adverse effects , Neoadjuvant Therapy/methods , Retrospective Studies , Risk Factors , Sentinel Lymph Node Biopsy/adverse effects , Upper Extremity , Young Adult
4.
BMC Nephrol ; 18(1): 288, 2017 Sep 06.
Article in English | MEDLINE | ID: mdl-28877681

ABSTRACT

BACKGROUND: Fibronectin glomerulopathy is a rare, inherited, autosomal dominant, glomerular disease characterized by proteinuria, microscopic hematuria, hypertension, massive glomerular deposits of fibronectin, and slow progression to end-stage renal failure. Because the incident of fibronectin glomerulopathy is extremely low, the pathophysiology, genetic abnormalities, epidemiology, and mechanisms remain to be elucidated. CASE PRESENTATION: We report a 21-year-old woman with fibronectin glomerulopathy, who had been diagnosed with persistent cloaca and congenital esophageal atresia at birth. She developed proteinuria and hematuria 7 months before admission. Urinary protein and serum creatinine levels were 3.38 g/gCr and 0.73 mg/dL. Renal biopsy showed severe mesangial widening due to massive deposits, which was positive periodic acid-Schiff and negative methenamine silver. Immunostaining was negative for immunoglobulin but positive for fibronectin. Electron microscopy showed diffuse mesangial granular deposits. Thus she was diagnosed with fibronectin glomerulopathy, despite a negative family history of kidney disease and lack of any known missense mutations of fibronectin 1 gene. CONCLUSION: We report a patient who developed fibronectin glomerulopathy during the clinical course of extremely rare congenital malformations, including persistent cloaca and congenital esophageal atresia. We describe a case of this condition in detail and summarize the 75 case reports of fibronectin glomerulopathy.


Subject(s)
Cloaca/pathology , Esophageal Atresia/diagnosis , Esophageal Atresia/genetics , Glomerulonephritis, Membranoproliferative/diagnosis , Glomerulonephritis, Membranoproliferative/genetics , Esophageal Atresia/complications , Female , Glomerulonephritis, Membranoproliferative/complications , Humans , Young Adult
5.
Case Rep Nephrol Dial ; 5(3): 187-91, 2015.
Article in English | MEDLINE | ID: mdl-26558252

ABSTRACT

Ceftriaxone (CTRX) is a third-generation cephalosporin widely used for the treatment of bacterial infections in patients with renal disease because of its excretion by both renal and hepatic mechanisms. Biliary pseudolithiasis is a known CTRX-associated complication; however, there have been no studies of this adverse event in adult patients receiving maintenance hemodialysis. Here we report the case of a 79-year-old Japanese woman with end-stage renal disease (ESRD) receiving maintenance hemodialysis who developed CTRX-induced pseudolithiasis. The patient received CTRX for bronchial pneumonia. Fifteen days following CTRX initiation, the patient presented with stomachache. Because of the presence of one gallstone and increased gallbladder wall thickness on computed tomography scans, not detected at the onset of pneumonia, the patient was diagnosed with CTRX-induced gallbladder pseudolithiasis. CTRX was discontinued immediately. At 48 days following CTRX withdrawal, the gallstone and thickening of the gallbladder wall had completely resolved. ESRD may be a risk factor for CTRX-induced pseudolithiasis as hepatic excretion of CTRX is the predominant clearance mechanism in patients with ESRD. More attention should be paid to CTRX-induced pseudolithiasis following the use of CTRX in ESRD patients.

SELECTION OF CITATIONS
SEARCH DETAIL
...